Cell Therapy Company Unleashes Revolutionary Trial Results For Chronic Myocardial Ischemia Treatment

Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide, innovative therapeutic interventions are critically needed to enhance patient outcomes and quality of life. One such promising advancement comes from BioCardia, Inc. (NASDAQ: BCDA), which has recently unveiled the primary endpoint results of the open label roll-in cohort of the CardiAMP® Cell Therapy in Chronic Myocardial Ischemia Trial. This groundbreaking study showcases significant patient benefits in key outcomes, heralding a new dawn in the treatment of refractory angina due to chronic myocardial ischemia. $BioCardia(BCDA.US)$